Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia
Launched by NINGBO NO. 1 HOSPITAL · May 25, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Underwent comprehensive health examinations at the Physical Examination Center of the First Affiliated Hospital of Ningbo University between 2017 and 2024;
- • 2. Aged 18 years or older at baseline;
- • 3. Completed an abdominal ultrasound examination during the health check-up.
- Exclusion Criteria:
- • 1. Underweight status at baseline, defined as BMI \< 18.5 kg/m² ；
- • 2. Missing data on height, weight, or components of the metabolic syndrome ;
- • 3. Baseline diagnosis of MASLD or any other liver diseases
- • 4. Baseline diagnosis of hyperuricemia
About Ningbo No. 1 Hospital
Ningbo No. 1 Hospital is a leading medical institution located in Ningbo, China, dedicated to advancing healthcare through innovative clinical research and trials. With a strong emphasis on patient-centered care, the hospital is equipped with state-of-the-art facilities and a multidisciplinary team of experienced professionals. As a clinical trial sponsor, Ningbo No. 1 Hospital aims to contribute to the development of new therapies and treatment protocols, ensuring the highest standards of safety and efficacy while fostering collaboration with national and international research organizations. Their commitment to excellence in clinical research underpins their mission to enhance patient outcomes and promote medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ningbo, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported